Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Hepatitis C

Antiviral treatment improves outcomes in patients with advanced cirrhosis

Hepatitis C drug shown to reduce the need for transplant and lower mortality rate in patients with advanced liver disease.

The effect of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection has not been well established in patients with decompensated cirrhosis, an advanced form of the disease that usually requires transplantation or it can be fatal.

In a study presented at the Joint International Congress of ILTS, ELITA & LICAGE in Prague, Czech Republic[1] (26 May 2017), researchers compared 623 people who received sofosbuvir in randomised trials with 1,857 untreated controls from a liver transplant waiting list.

At 48 weeks, 95% of patients in the sofosbuvir group were alive and had not undergone transplant compared with 30% of controls. The liver transplant rate was only 3% in sofosbuvir patients compared with 43% among controls.

HCV treatment should be considered for patients with decompensated cirrhosis, the researchers conclude.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20203089

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Liver transplant, operating room

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.